CompletedNCT00796276

A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone

Medication studyAges 18–55Schizophrenia

The study in practice

Understand this study

Listed age limits: 18 years to 55 years.

Study clarity

Study start dateMay 2004

Recruitment status: Completed
Enrollment listed in the registry: 20
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 55 Years
Official registry ID: NCT00796276
Official title: Show the full official title
Disposition of Paliperidone Enantiomers After Treatment With Different Formulations of the Racemate and the Separate Enantiomers and the Determination of the Absolute Bioavailability of IR and ER OROS Paliperidone

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including IR OROS paliperidone and ER OROS paliperidone.

Who was this study for?

Listed age limits: 18 years to 55 years.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.